Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Transcode Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 15 | 10 | −5 |
| Shares | 262.1K | 325.3K | +63.2K (+24.1%) |
| Value | $263.0K | $185.8K | −$77.2K (−29.4%) |
New holders (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 39,706 | $22.7K | 0.00% |
| FMR LLC | 175 | $100 | 0.00% |
| Danske Bank A/S | 2 | $1 | 0.00% |
Sold out (8)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| UBS Group AG | 74,924 | $75.3K |
| Citadel Advisors LLC | 25,512 | $25.6K |
| Susquehanna International Group, LLP | 24,253 | $24.4K |
| Virtu Financial LLC | 18,358 | $18.0K |
| Two Sigma Securities, LLC | 12,854 | $12.9K |
| Financial Network Wealth Advisors LLC | 1,000 | $1.00K |
| First Personal Financial Services | 1 | $1 |
| Royal Bank of Canada | 1 | $0 |